1.67
price up icon1.21%   0.02
after-market Handel nachbörslich: 1.66 -0.01 -0.60%
loading
Schlusskurs vom Vortag:
$1.65
Offen:
$1.63
24-Stunden-Volumen:
1.64M
Relative Volume:
1.19
Marktkapitalisierung:
$99.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-144.01M
KGV:
-0.4165
EPS:
-4.01
Netto-Cashflow:
$-113.02M
1W Leistung:
-9.49%
1M Leistung:
-13.47%
6M Leistung:
+3.09%
1J Leistung:
-83.96%
1-Tages-Spanne:
Value
$1.5706
$1.68
1-Wochen-Bereich:
Value
$1.5706
$1.89
52-Wochen-Spanne:
Value
$1.2905
$12.85

Biomea Fusion Inc Stock (BMEA) Company Profile

Name
Firmenname
Biomea Fusion Inc
Name
Telefon
(650) 980-9099
Name
Adresse
1599 INDUSTRIAL ROAD, SAN CARLOS
Name
Mitarbeiter
63
Name
Twitter
Name
Nächster Verdiensttermin
2025-05-02
Name
Neueste SEC-Einreichungen
Name
BMEA's Discussions on Twitter

Vergleichen Sie BMEA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BMEA
Biomea Fusion Inc
1.67 116.66M 0 -144.01M -113.02M -4.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
412.22 104.45B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
469.36 60.95B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.60 59.11B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.95 49.23B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.94 35.92B 4.56B -176.77M 225.30M -1.7177

Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-08-28 Eingeleitet Jefferies Buy
2025-06-03 Fortgesetzt Piper Sandler Overweight
2024-10-09 Eingeleitet Edward Jones Buy
2024-09-27 Hochstufung Rodman & Renshaw Neutral → Buy
2024-09-27 Hochstufung Truist Hold → Buy
2024-08-29 Eingeleitet CapitalOne Overweight
2024-06-11 Herabstufung Truist Buy → Hold
2024-06-07 Herabstufung Barclays Overweight → Equal Weight
2024-04-02 Herabstufung JP Morgan Overweight → Neutral
2024-02-06 Eingeleitet Truist Buy
2023-07-27 Eingeleitet Scotiabank Sector Outperform
2023-06-26 Herabstufung Jefferies Buy → Hold
2023-05-12 Eingeleitet Barclays Overweight
2023-03-29 Bestätigt Oppenheimer Outperform
2023-03-28 Bestätigt H.C. Wainwright Buy
2023-02-24 Eingeleitet Citigroup Buy
2022-06-02 Fortgesetzt H.C. Wainwright Buy
2022-01-12 Eingeleitet H.C. Wainwright Buy
2021-12-17 Eingeleitet Oppenheimer Outperform
2021-05-11 Eingeleitet JP Morgan Overweight
2021-05-11 Eingeleitet Jefferies Buy
2021-05-11 Eingeleitet Piper Sandler Overweight
Alle ansehen

Biomea Fusion Inc Aktie (BMEA) Neueste Nachrichten

pulisher
08:14 AM

H.C. Wainwright reiterates Buy rating on Biomea Fusion stock amid investor concerns By Investing.com - Investing.com Australia

08:14 AM
pulisher
06:56 AM

How geopolitical tensions affect Biomea Fusion Inc. stockQuarterly Investment Review & Daily Oversold Bounce Ideas - newser.com

06:56 AM
pulisher
05:51 AM

Real time pattern detection on Biomea Fusion Inc. stock2025 Market Trends & Fast Entry High Yield Stock Tips - newser.com

05:51 AM
pulisher
01:32 AM

Is Biomea Fusion Inc. stock trading at a premium valuationPortfolio Growth Summary & Low Drawdown Trading Techniques - newser.com

01:32 AM
pulisher
Oct 13, 2025

Can Biomea Fusion Inc. stock hit analyst price targetsJuly 2025 Recap & Fast Gain Swing Alerts - newser.com

Oct 13, 2025
pulisher
Oct 12, 2025

Is Biomea Fusion Inc. meeting your algorithmic filter criteriaJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com

Oct 12, 2025
pulisher
Oct 10, 2025

Biomea Fusion Inc. stock retracement – recovery analysisWeekly Trading Summary & Safe Entry Momentum Stock Tips - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Should you wait for a breakout in Biomea Fusion Inc.Portfolio Value Summary & Fast Exit and Entry Strategy Plans - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Biomea Fusion (NASDAQ:BMEA) Trading Up 6.5%What's Next? - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

A Fresh Look at Biomea Fusion's (BMEA) Valuation Following Clinical Milestone and $25M Equity Raise - Sahm

Oct 10, 2025
pulisher
Oct 10, 2025

Tools to assess Biomea Fusion Inc.’s risk profileMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Biomea Fusion (NASDAQ:BMEA) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Does Biomea Fusion Inc. fit your quant trading model2025 Market Overview & Precise Swing Trade Entry Alerts - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

What analysts say about Biomea Fusion Inc stockBollinger Bands Signals & Free Unmatched Market Gains - earlytimes.in

Oct 08, 2025
pulisher
Oct 08, 2025

Why Biomea Fusion (BMEA) Is Up After Positive Diabetes Data and $25M Equity Raise – And What’s Next - Yahoo Finance

Oct 08, 2025
pulisher
Oct 08, 2025

Biomea Fusion Announces Positive Phase II Study Results - MSN

Oct 08, 2025
pulisher
Oct 08, 2025

Why Biomea Fusion (BMEA) Is Up on Promising Phase II Diabetes Data and What It Could Mean Next - simplywall.st

Oct 08, 2025
pulisher
Oct 07, 2025

Nasdaq Tumbles 200 Points; Trilogy Metals Shares Spike Higher - Benzinga

Oct 07, 2025
pulisher
Oct 07, 2025

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups - insights.citeline.com

Oct 07, 2025
pulisher
Oct 07, 2025

Biomea Fusion prices $25 million public offering of shares and warrants - Investing.com Nigeria

Oct 07, 2025
pulisher
Oct 07, 2025

Biomea’s ‘durable’ menin inhibitor advancing in hard-to-treat diabetes - BioWorld MedTech

Oct 07, 2025
pulisher
Oct 07, 2025

Biomea Fusion: Surging On Data, Sinking On FundingI'm On The Sidelines - Seeking Alpha

Oct 07, 2025
pulisher
Oct 07, 2025

Traders Purchase High Volume of Biomea Fusion Call Options (NASDAQ:BMEA) - MarketBeat

Oct 07, 2025
pulisher
Oct 07, 2025

Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study - inkl

Oct 07, 2025
pulisher
Oct 07, 2025

Dow Jumps Over 100 Points; McCormick Earnings Top Views - Benzinga

Oct 07, 2025
pulisher
Oct 07, 2025

Biomea Fusion announces pricing of public offering of securities - MSN

Oct 07, 2025
pulisher
Oct 07, 2025

Biomea Fusion plunges on $25 mln stock-and-warrants offering - TradingView

Oct 07, 2025
pulisher
Oct 07, 2025

Biomea Fusion Announces Pricing of Public Offering of Securities - The Manila Times

Oct 07, 2025
pulisher
Oct 07, 2025

D. Boral Capital Maintains Biomea Fusion (BMEA) Buy Recommendation - Nasdaq

Oct 07, 2025
pulisher
Oct 07, 2025

$25M Offering: Biomea Fusion Prices 11.2M Shares & Warrants at $2.05 — Closing Oct 8, 2025 - Stock Titan

Oct 07, 2025
pulisher
Oct 06, 2025

Biomea Fusion announces proposed public offering of securities - MarketScreener

Oct 06, 2025
pulisher
Oct 06, 2025

Biomea Fusion, Inc. (BMEA) Stock: Volatile Surge Ahead of Jefferies-Led Equity Offering - parameter.io

Oct 06, 2025
pulisher
Oct 06, 2025

Biomea's diabetes drug shows promise, may work for those not responding to GLP-1 - MarketScreener

Oct 06, 2025
pulisher
Oct 06, 2025

Biomea announces positive 52-week results from phase II COVALENT-111 study in type 2 diabetes - MarketScreener

Oct 06, 2025
pulisher
Oct 06, 2025

Biomea Fusion Reports Phase 2 Data in Diabetes, Launches Stock Offering - MarketScreener

Oct 06, 2025
pulisher
Oct 06, 2025

Biomea Fusion Announces Proposed Public Offering of Securities - GlobeNewswire

Oct 06, 2025
pulisher
Oct 06, 2025

Biomea Fusion launches public offering of common stock and warrants - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Biomea Fusion launches public offering of common stock and warrants By Investing.com - Investing.com Australia

Oct 06, 2025
pulisher
Oct 06, 2025

Biomea Fusion reports 52-week results from Phase II diabetes trial - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent

Oct 06, 2025
pulisher
Oct 06, 2025

Biomea Fusion Reports Positive 52-Week Results from Phase II COVALENT-111 Study of Icovamenib in Type 2 Diabetes Patients - Quiver Quantitative

Oct 06, 2025
pulisher
Oct 06, 2025

Biomea Fusion Announces Positive 52-Week Results from Phase - GlobeNewswire

Oct 06, 2025
pulisher
Oct 06, 2025

1.8% HbA1c reduction sustained at Week 52 — Biomea Fusion's icovamenib shows durable benefit - Stock Titan

Oct 06, 2025
pulisher
Oct 06, 2025

Why Biomea Fusion Inc. stock remains undervaluedTrade Risk Summary & Safe Entry Zone Identification - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Visualizing Biomea Fusion Inc. stock with heatmapsVolume Spike & Weekly High Potential Alerts - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Biomea Fusion (NASDAQ:BMEA) Receives “Buy” Rating from D. Boral Capital - Defense World

Oct 04, 2025
pulisher
Oct 03, 2025

BMEA: D. Boral Capital Maintains Buy Rating with $16 PT | BMEA S - GuruFocus

Oct 03, 2025
pulisher
Oct 03, 2025

Biomea Fusion's (BMEA) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat

Oct 03, 2025
pulisher
Oct 01, 2025

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 01, 2025
pulisher
Oct 01, 2025

Biomea Fusion, Inc. reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Oct 01, 2025

Finanzdaten der Biomea Fusion Inc-Aktie (BMEA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.75
price down icon 5.15%
$85.96
price up icon 1.45%
$32.75
price up icon 0.21%
$102.61
price up icon 0.30%
$161.38
price down icon 1.56%
biotechnology ONC
$320.94
price down icon 1.86%
Kapitalisierung:     |  Volumen (24h):